新辅助化疗对Ⅲ期中低位直肠癌患者肿瘤细胞增殖能力及CD4^(+)、CD8^(+)T淋巴细胞的影响研究  

Effect of Neoadjuvant Chemotherapy on the Proliferative Ability of Tumor Cells and CD4^(+),CD8^(+)T Lymphocytes in StageⅢMiddle and Low Rectal Cancer

作　　者：潘平 许禹[2] 朱征全 Pan Ping;Xu Yu;Zhu Zhengquan(The Second Department of Medical Oncology,First People’s Hospital of Nanyang,Nanyang,Henan,473000,China)

机构地区：[1]南阳市第一人民医院肿瘤内二科,河南南阳473000 [2]南阳市中心医院影像科,河南南阳473000 [3]南阳市第一人民医院肝胆胰脾外科,河南南阳473000

出　　处：《黑龙江医学》2024年第23期2851-2853,共3页Heilongjiang Medical Journal

摘　　要：目的:探讨新辅助化疗对Ⅲ期中低位直肠癌患者肿瘤细胞增殖能力及CD4^(+)、CD8^(+)T淋巴细胞的影响。方法:选取2020年1月—2023年2月南阳市第一人民医院收治的80例Ⅲ期中低位直肠癌患者作为研究对象,根据治疗方案的不同将其分为对照组和观察组,每组各40例。对照组患者接受手术治疗,观察组患者在对照组的基础上接受新辅助化疗。比较两组患者手术效果,比较两组患者治疗前后肿瘤细胞增殖指数及T淋巴细胞(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))水平。结果:两组患者手术切除率比较,差异无统计学意义(χ^(2)=0.213,P>0.05);观察组患者保肛率、术后病理学完全缓解率均高于对照组患者,差异均有统计学意义(χ^(2)=5.000、4.943,P<0.05);治疗后,两组患者肿瘤细胞增殖指数低于治疗前,且观察组患者低于对照组患者,差异有统计学意义(t=9.268,P<0.05);治疗后,两组患者CD4^(+)、CD4^(+)/CD8^(+)水平均高于治疗前,且观察组患者均高于对照组患者,两组患者CD8^(+)T水平低于治疗前,且观察组患者低于对照组患者,差异均有统计学意义(t=5.029、13.717、10.256,P<0.05)。结论:新辅助化疗对Ⅲ期中低位直肠癌患者的治疗效果显著,能够有效抑制其肿瘤细胞增殖,提高其免疫功能。Objective:To investigate the effects of neoadjuvant chemotherapy on the proliferation ability of tumor cells and CD4^(+),CD8^(+)T lymphocytes in stageⅢmiddle and low rectal cancer.Methods:A retrospective analysis was conducted on 80 patients with stageⅢmid to low rectal cancer in the First People’s Hospital of Nanyang City from January 2020 to February 2023.According to different treatment plans,the two groups were divided into control group and observation group,with 40 patients in each group.Among them,the control group received only surgical treatment,while the observation group received neoadjuvant therapy and surgical treatment,and neoadjuvant chemotherapy was completed 2 weeks before surgical treatment.The surgical effects of the two groups of patients were compared and analyzed,including the tumor cell proliferation index and T lymphocytes(CD4^(+),CD8^(+),CD4^(+)/CD8^(+)).Results:There was no statistically significant difference in the surgical resection rate between the two groups of patients(χ^(2)=0.213,P>0.05).The observation group had a higher anal preservation rate and a higher postoperative pathological complete response rate than the control group,with statistically significant difference(χ^(2)=5.000,4.943;P<0.05).After treatment,the tumor cell proliferation index and CD8^(+)T cells of the observation group were lower than those of the control group,and the CD4^(+)T cells and CD4^(+)/CD8^(+)ratio were higher than those of the control group,with statistically significant difference(t=5.029,13.717,10.256;P<0.05).Conclusion:The application of neoadjuvant chemotherapy in the treatment of stageⅢmiddle and low rectal cancer patients has significant surgical effect,which can effectively inhibit the proliferation of tumor cells,improve the patient’s immune function,and thus improve the ther prognosis.

关 键 词：新辅助化疗 Ⅲ期中低位直肠癌 肿瘤细胞增殖能力 CD4^(+)、CD8^(+)T淋巴细胞 

分 类 号：R735.37[医药卫生—肿瘤]